Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Study Evaluating the Effect of Tusamitamab Ravtansine on the QTc Interval in Participants With Metastatic Solid Tumors

NCT05429762 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05429762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05429762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Study Evaluating the Effect of Tusamitamab Ravtansine on the QTc Interval in Participants With Metastatic Solid Tumors
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Terminated
Start date
October 3, 2022
Completion date
April 10, 2024
Enrollment
56 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm